Finger loop inhibitors of the HCV NS5B polymerase: Discovery and prospects for new HCV therapy

Current Opinion in Drug Discovery and Development

Volumn 9, Issue 5, 2006, Pages 618-626

  Beaulieu, Pierre L ^a  

^a BOEHRINGER INGELHEIM CANADA LTD   (Canada)

Author keywords

Finger loop inhibitor; HCV; Hepatitis C virus; NS5B polymerase; RNA

Indexed keywords

BENZIMIDAZOLE 5 CARBOXYLIC ACID DERIVATIVE; CARBOXYLIC ACID DERIVATIVE; CILUPREVIR; INDOLE DERIVATIVE; JTK 003; N ACETAMIDOINDOLE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; RNA DIRECTED RNA POLYMERASE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DRUG ACTIVITY; DRUG RESEARCH; DRUG STRUCTURE; ENZYME INHIBITION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTIVIRAL AGENTS; HEPATITIS C; HUMANS; VIRAL NONSTRUCTURAL PROTEINS;

EID: 33748617118     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Choo Q-L, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M: Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science (1989) 244(4902):359-362. Seminal paper on the discovery of HCV as the etiological agent for non-A and non-B hepatitis.
2. Hoofnagle JH: Course and outcome of hepatitis C. Hepatology (2002) 36(5 Suppl 1):S21-S29
3. Feld JJ, Hoofnagle JH: Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature (2005) 436(7053):967-972.
4. Hijikata M, Kato N, Ootsuyama Y, Nakagawa M, Shimotohno K: Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis. Proc Natl Acad Sci USA (1991) 88(13):5547-5551.
5. Grakoui A, Wychowski C, Lin C, Feinstone SM, Rice CM: Expression and identification of hepatitis C virus polyprotein cleavage products. J Virol (1993) 67(3):1385-1395.
6. Lohmann V, Körner F, Koch J, Herian U, Theilmann L, Bartenschlager R: Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science (1999) 285(5424):110-113. First report of a cell-based assay that supports replication of subgenomic HCV RNA and allows in vitro profiling of potential antiviral compounds in cell culture
7. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Krausslich H-G, Mizokami M, Bartenschlager R et al: Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med (2005) 11(7):791-796. First report on production of infectious HCV particles in tissue culture.
8. Lindenbach BD, Evans MJ, Syder AJ, Wölk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM: Complete replication of hepatitis C virus in cell culture. Science (2005) 309(5734):623-626.
9. Hinrichsen H, Benhamou Y, Wedemeyer H, Reiser M, Sentjens RE, Calleja JL, Foms X, Erhardt A, Cröenlein J, Chaves R, Yong C-L et al: Short term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology (2004) 127(5):1347-1355. First report on the short-term clinical efficacy of a small-molecule anti-HCV drug in patients infected with HCV genotype 1.
10. Lamarre D, Anderson PC, Bailey M, Beaulieu P, Bolger G, Bonneau P, Bös M, Cameron DR, Cartier M, Cordingley MC, Faucher A-M et al: An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature (2003) 426(6963):186-189.
11. Pemi RB, Almquist SJ, Byrn RA, Chandorkar G, Chaturvedi PR, Courtney LF, Decker CJ, Dinehart K, Gates CA, Harbeson SL, Heiser A et al: Preclinical profile of VX-950, a potent, selective, and orally bioavallable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother (2006) 50(3):899-909.
12. Malcom BA, Liu R, Lahser F, Agrawal S, Belanger B, Butkiewicz N, Chase R, Gheyas F, Hart A, Hesk D, Ingravallo P et al: SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of α Interferon in replicon cells. Antimicrob Agents Chemother (2006) 50(3):1013-1020.
13. Behrens SE, Tomei L, De Francesco R: Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. EMBO J(1996) 15(1):12-22.
14. Beaulieu PL, Tsantrizos YS: Inhibitors of the HCV NS5B polymerase: New nope for the treatment of hepatitis C infections. Curr Opin Invest Drugs (2004) 5(8):838-850.
15. Ago H, Adachi T, Yoshida A, Yamamoto M, Habuka N, Yatsunami K, Miyano M: Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Structure (1999) 7(11):1417-1426.
16. Bressanelli S, Tomei L, Roussel A, Incitti I, Vitale RL, Mathieu M, De Francesco R, Rey FA: Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc Natl Acad Sci USA (1999) 96(23):13034-13039.
17. McKercher G, Beaulieu PL, Lamarre D, LaPlante S, Lefebvre S, Pellerin C, Thauvette L, Kukolj G: Specific inhibitors of HCV polymerase identified using an NS5B with lower affinity for template/primer substrate. Nucleic Acids Res (2004) 32(2):422-431.
18. Hirashima S, Suzuki T, Ishida T, Noji S, Yata S, Ando I, Komatsu M, Ikeda S, Hashimoto H: Benzimidazole derivatives bearing substituted biphenyls as hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors: Structure-activity relationship studies and identification of a potent and highly selective inhibitor JTK-109. J Med Chem (2006) 49(15):4721-4736.
19. Tomei L, Altamura S, Bartholomew L, Biroccio A, Ceccacci A, Pacini L, Narjes F, Gennari N, Bisbocci M, Incitti I, Orsatti L et al. Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. J Virol (2003) 77(24):13225-13231.
20. Beaulieu PL, Haché B, von Moos E: A practical Oxone®-mediated, high-throughput, solution-phase synthesis of benzimidazoles from 1,2-phenylenediamines and aldehydes and its application to preparative scale synthesis. Synthesis (2003) (11):1683-1692.
21. Beaulieu PL, Bös M, Bousquet Y, Fazal G, Gauthier J, Gillard J, Goulet S, LaPlante S, Poupart M-A, Lefèbvre S, McKercher G et al: Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: Discovery and preliminary SAR of benzimidazole derivatives. Bioorg Med Chem Lett (2004) 14(1):119-124.
22. McHutchison JG, Patel K: Future therapy of hepatitis C. Hepatology (2002) 36(5 Suppl 1):S245-S252.
23. Beaulieu PL, Bös M, Bousquet Y, DeRoy P, Fazal G, Gauthier J, Gillard J, Goulet S, McKercher G, Poupart M-A, Valois S et al: Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: Discovery of benzimidazole 5-carboxylic amide derivatives with low-nanomolar potency. Bioorg Med Chem Lett (2004) 14(4):967-971.
24. Beaulieu PL, Bousquet Y, Gauthier J, Gillard J, Marquis M, McKercher G, Pellerin C, Valois S, Kukolj G: Non-nucleoside benzimidazole-based allosteric inhibitors of the hepatitis C virus NS5B polymerase: Inhibition of subgenomic hepatitis C virus RNA replicons in Huh-7 cells. J Med Chem (2004) 47(27):6884-6892.
25. LaPlante SR, Jakalian A, Aubry N, Bousquet Y, Ferland J-M, Gillard J, Lefèbvre S, Poirier M, Tsantrizos Y, Kukolj G, Beaulieu PL: Binding mode determination of benzimidazole inhibitors of the hepatitis C virus RNA polymerase by a structure and dynamics strategy. Angew Chem Int Ed (2004) 43(33):4306-4311.
26. Kukolj G, McGibbon GA, McKercher G, Marquis M, Lefèbvre S, Thauvette L, Gauthier J, Goulet S, Poupart M-A, Beaulieu PL: Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase. J Biol Chem (2005) 280(47):39260-39267.
27. Beaulieu PL, Gillard J, Bykowski D, Brochu C, Dansereau N, Duceppe JS, Haché B, Jakalian A, Lagacé L, LaPlante S, McKercher G, Moreau E, Perreault S, Stammers T, Thauvette L, Warrington J, Kukolj G: Improved replicon cellular activity of non-nucleoside allosteric inhibitors of HCV NSSB polymerase: From benzimidazole to indole scaffolds. Bioorg Med Chem Lett (2006): in press.
28. Harper S, Pacini B, Avolio S, Di Filippo M, Migliaccio G, Laufer R, De Francesco R, Rowley M, Narjes F: Development and preliminary optimization of indole-N-acetamide inhibitors of hepatitis C virus NS5B polymerase. J Med Chem (2005) 48(5):1314-1317.
29. Harper S, Avolio S, Pacini B, Di Filippo M, Altamura S, Tomei L, Paonessa G, Di Marco S, Carfi A, Giuliano C, Padron G: Potent inhibitors of subgenomic hepatitis C virus RNA replication through optimization of indole-N-acetamide allosteric inhibitors of the viral NS5B polymerase. J Med Chem (2005) 48(14):4547-4557.
30. Giuliano C, Fiore F, Di Marco A, Padron Velazquez J, Bishop A, Bonelli F, Gonzalez-Paz O, Marcucci I, Harper S, Narjes F, Pacini B et al: Preclinical pharmacokinetics and metabolism of a potent non-nucleoside inhibitor of the hepatitis C virus NSSB polymerase. Xenobiotica (2005) 35(10/11):1035-1054.
31. Di Marco S, Volpari C, Tomei L, Altamura S, Harper S, Narjes F, Koch U, Rowley M, De Francesco R, Migliaccio G, Carfi A: Interdomain communication in hepatitis C virus polymerase abolished by small molecule inhibitors bound to a novel allosteric site. J Biol Chem (2005) 280(33):29765-29770.